Psoriatic Arthritis (PsA)
Dermatology·MeSH: Arthritis, Psoriatic
Prevalence
133.0 / 100K
Incidence
6.0 / 100K/yr
7 drugs in development·7 companies·3 clinical trials
Drug Pipeline by Phase
Approved(4)
Phase 2(1)
| Drug | Company |
|---|---|
| SPY072 | Spyre Therapeutics, Inc. (SYRE) |
Phase 1(1)
Phase 4(1)
| Drug | Company |
|---|---|
| Deucravacitinib | Valneva SE (VALN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Psoriatic Arthritis (PsA)?
BioSniper tracks 7 drugs in development for Psoriatic Arthritis (PsA) across 7 companies.
How many clinical trials target Psoriatic Arthritis (PsA)?
There are 3 clinical trials targeting Psoriatic Arthritis (PsA) tracked by BioSniper.
What is the prevalence of Psoriatic Arthritis (PsA)?
The estimated prevalence of Psoriatic Arthritis (PsA) is approximately 133.0 per 100,000 population.
Deep-dive into Psoriatic Arthritis (PsA)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis